Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
ABOUT US
Geoffroy de Chabot-Tramecourt
Janssen PMP
An Evolution in
Innovation Management
Agenda
ABOUT US
• Janssen PMP
2
OUR ACTIVITIES
ABOUT US
BUSINESS AREAS
Post-Harvest Microbial Control
Fungicides Industrial protection
Imazalil Antifouling
Pyrimethanil Health & Hygiene
Physiological
products
1-MCP
3
ABOUT US
Innovation at
Johnson & Johnson is about
creating strong networks of
people who can combine
resources, ideas and
technologies in a new way.
Paul Stoffels, MD
Executive Vice President and Chief Scientific Officer Johnson
& Johnson
4
A BJ aOnUsTs eUnS P M P
Conservative market
Slow adoption of
innovations
Azoxystrobin
Patent filed
Fludioxonil
First article
Pyrimethanil
On the market
Propiconazole
Prochloraz
Imazalil
Thiabendazole
Ortho-Phenyl Phenol
1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020
ABOUT US
Driver
for
M&A
Where
A B O U T to
U S place our efforts at Janssen PMP ?
TRANSFORMATIONAL
10% Developing breakthroughs
and inventing things for
20% markets that don’t yet exist
Corporate venturing,
ADJACENT hackathons,
Expanding Boot camps
intrapreneurship
from existing
business into
70% “new to the
CORE company”
Optimizing business
existing
Roadmaps
products for
Stage-gated innovation existing
NPD processes customers
Source: Nagji & Tuff (2012)
Closed
A B O U Tinnovation
US versus open innovation
1. All the smart people … 1. … in our organization. 1. … in & out our organization.
2. R&D 2. Everything ourselves 2. Also external R&D
3. Be the first to 3. A technology that comes from our 3. A discovery that does not have to be
commercialize research ours.
4. The best ideas …
4. … have to come from us to win the 4. If we make better use of external and
battle. internal ideas and unify the knowledge
5. Control over the created, we will win.
innovation process 5. We should optimize innovation
5. If we have full control over the management (in & out-licensing)
innovation process our rivals will not be
able to profit from our innovative ideas.
J&JA BInnovation
OUT US Matrix
JLABS
Internal activities
10
Significantly
ABOUT US increase the level of innovation
Speed
Level of innovation
Differentiated
product
Higher
treshold
VALUE
Too
late
Time
11
Past
A B Oversus
U T U S future at Janssen PMP
Past Now
• Before 2001:
• 80 000 substances screened until 2001 > 0 in our • Many partnerships at several levels
portfolio • From early stage to late development
• 2000 – 2010 :
• > 250 ai’s evaluated > 9 in our portfolio
14
yet2
A B O collaboration
UT US with Janssen PMP
Value created:
Canvassed the Sept. 2018 Oct. 2018 Jan. 2019 Feb. 2019
market Kick-off
Marketing Guiding the
Evaluations
the tech process
• >200 reached
• 24 sought more
info
• 4 technical
evaluations
Focused – Efficient – Comprehensive
15
ABOUT US Conclusion
1. Focus
2. Open
innovation
3. Expertise
16